RhumbLine Advisers’s Chemomab Therapeutics CMMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.8K Buy
18,366
+510
+3% +$871 ﹤0.01% 3677
2025
Q4
$29.5K Buy
17,856
+8,351
+88% +$22.2K ﹤0.01% 3719
2025
Q3
$25K Sell
9,505
-464
-5% -$1.71K ﹤0.01% 3751
2025
Q2
$46.2K Buy
9,969
+4,007
+67% +$19.8K ﹤0.01% 3677
2025
Q1
$26K Buy
5,962
+10
+0.2% +$70 ﹤0.01% 3697
2024
Q4
$43.1K Sell
5,952
-941
-14% -$5.94K ﹤0.01% 3682
2024
Q3
$43.3K Buy
6,893
+1,924
+39% +$10.8K ﹤0.01% 3701
2024
Q2
$18.3K Buy
4,969
+312
+7% +$1.08K ﹤0.01% 3885
2024
Q1
$14.5K Hold
4,657
﹤0.01% 3810
2023
Q4
$9.5K Buy
4,657
+3,946
+555% +$10.4K ﹤0.01% 3870
2023
Q3
$2.54K Sell
711
-40
-5% -$187 ﹤0.01% 4089
2023
Q2
$3.94K Buy
+751
New +$4.74K ﹤0.01% 4123

Other funds holding CMMB

RhumbLine Advisers's CMMB Position: Q1 2026 in Review

RhumbLine Advisers increased its Chemomab Therapeutics (CMMB) stake by 2.9% in Q1 2026, buying an estimated $871 and bringing the position to 18,366 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

RhumbLine Advisers first reported a position in CMMB in Q2 2023 and has held it in 12 quarters since. The position peaked at $46.2K in Q2 2025. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • RhumbLine Advisers held 18,366 shares of Chemomab Therapeutics worth $28.8K as of Q1 2026.
  • RhumbLine Advisers bought 510 Chemomab Therapeutics shares in Q1 2026, an estimated $871.
  • Chemomab Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3677 holding.
  • RhumbLine Advisers first reported a position in Chemomab Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • RhumbLine Advisers's Chemomab Therapeutics position peaked at $46.2K in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.